Cargando…
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
BACKGROUND: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. METHODS: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dos...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Society for Bone and Mineral Research
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973401/ https://www.ncbi.nlm.nih.gov/pubmed/33730783 http://dx.doi.org/10.11005/jbm.2021.28.1.51 |